Camonsertib is under clinical development by Repare Therapeutics and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Camonsertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Camonsertib overview

RP-3500 is under development for the treatment of solid tumor including ovarian cancer, breast cancer, metastatic non-small cell lung cancer (NSCLC), pancreatic cancer, head and neck cancer squamous cell carcinoma, melanoma, hormone refractory (castration resistant, androgen-independent) prostate cancer, relapsed and refractory chronic lymphocytic leukemia (CLL). It is administered through oral route. The drug candidate is developed based on CRISPR-enabled synthetic lethality drug discovery platform. It acts by targeting ataxia telangiectasia and Rad3 related protein (ATR).

Repare Therapeutics overview

Repare Therapeutics is a clinical-stage precision oncology company. Its products include lunresertib, a PKMYT1 inhibitor, camonsertib, an ATR inhibitor, RP-1664, a PLK4 inhibitor, and RP-3467, a Polo ATPase inhibitor. Repare Therapeutic utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company operates under the brand SNIPRx. It operates in the US and Canada. Repare Therapeutics is headquartered in St-Laurent, Quebec, Canada.

For a complete picture of Camonsertib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.